WC
VERA icon

Wexford Capital’s Vera Therapeutics VERA Stock Holding History

Wexford Capital’s Portfolio VERA Stock Details VERA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-6,864
Closed -$162K – 458
2025
Q2 		$162K Sell
6,864
-35,441
-84% -$797K 0.05% 181
2025
Q1 		$1.02M Sell
42,305
-1,216
-3% -$39.1K 0.26% 74
2024
Q4 		$1.84M Sell
43,521
-3,334
-7% -$148K 0.29% 49
2024
Q3 		$2.07M Hold
46,855
– – 0.5% 46
2024
Q2 		$1.7M Buy
46,855
+40,766
+670% +$1.62M 0.43% 43
2024
Q1 		$263K Buy
+6,089
New +$217K 0.05% 186

Other funds holding VERA

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wexford Capital's VERA Position: Q3 2025 in Review

Wexford Capital sold out of Vera Therapeutics (VERA) in Q3 2025, closing a stake of 6,864 shares — an estimated $162K sold.

Wexford Capital first reported a position in VERA in Q1 2024 and held it in 6 quarters. The position peaked at $2.07M in Q3 2024. 175 funds tracked by Wall St. Rank hold VERA as of Q3 2025.

  • Wexford Capital reported no remaining Vera Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Wexford Capital sold 6,864 Vera Therapeutics shares in Q3 2025, an estimated $162K.
  • Wexford Capital first reported a position in Vera Therapeutics in Q1 2024 and held it in 6 quarters.
  • Wexford Capital's Vera Therapeutics position peaked at $2.07M in Q3 2024.
  • 175 funds tracked by Wall St. Rank held Vera Therapeutics as of Q3 2025.

Based on Wexford Capital's 13F filing for Q3 2025, filed 14 Nov 2025.